Remote monitoring after heart valve replacement for aortic valve stenosis
Tests home monitoring devices after TAVI in people with aortic valve stenosis.
Key facts
- Who runs it
- Imperial College London
- Where
- London, United KingdomSee the site
- Trial code
- Registry title
- Remote Cardiovascular Monitoring in Post-TAVI Patients
- Status
- Recruiting
- People taking part
- 216 people, planned
- Started
- 1 Nov 2024
- Expected to end
- 1 Jul 2028
- Type of study
- Interventional, 2 groupsOne group gets an existing treatment, for comparison.
- Treatments tested
- Remote Patient Monitoring Strategy
- Standard Medical Therapy
- Record updated
- 3 March 2026
Who can take part
AI summary
From the trial's eligibility criteria. Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.
The trial is looking for adults who just had TAVI (a heart valve replacement through a blood vessel) and can go home the same day. Some will use remote heart monitoring devices at home; others will get standard care.
- Age
- 18 years or older
- Sex
- All sexes
- Disease stage
- After a TAVI procedure, without serious complications that need a hospital stay. Bleeding at the access site is controlled, the person is awake and oriented, there is no large fluid around the heart, and they can walk comfortably.
- Earlier treatment
- Must have just had TAVI. People with a permanent pacemaker or other implanted pacing device, old or new, cannot join.
Main reasons for not taking part
- Unstable blood pressure or circulation after TAVI, cardiac arrest during the procedure, stroke, or sudden kidney injury
- Major or life-threatening bleeding needing a blood transfusion
- A permanent implanted pacing device
- The valve device could not be delivered, or major blood vessel access problems need a hospital stay
- Unable to use the technology or serious communication barriers
The registry criteria, word for word
Show all 16 criteriaShow less
Who can take part
- Patient age must be 18 years or above
- Post-TAVI patients without serious complications hindering same-day discharge, including vascular, neurological, and cardiac postprocedural complications necessitating inpatient care:
- Vascular: Controlled with adequate vascular hemostasis
- Neurological: Conscious and oriented, not under the effect of residual sedation
- Cardiac: No significant pericardial effusion
- Elective non-emergent patient admission and nonelective cases fitting discharge criteria
- Comfortable ambulation post-procedure
- The patient or their caregiver must have access to a smart device
- Ability to provide informed consent (the patient must be alert and oriented for consent)
- Adequate social support
Who cannot take part
- Hemodynamically unstable post-TAVI condition, periprocedural cardiac arrest, cerebral vascular accident, acute kidney injury (AKI) and major/life-threatening bleeding requiring blood transfusion
- Procedural failure in device delivery
- Patients with a permanent (pre-existing or new) implanted pacing device
- Major vascular access complications require patients to stay
- Inability to engage with the technology
- Significant communication barrier
Where in United Kingdom
- Hammersmith HospitalLondon, United KingdomContact: Adam Hartley, MBChB PhD (principal investigator)Taking people
About the trial
What the trial wants to find out
The goal of this randomised clinical trial is to utilise a remote monitoring algorithm to gather essential clinical data, aiming to guide the management of post-Transcatheter Aortic Valve Implantation (TAVI) patients and reduce both postprocedural hospital length of stay and readmissions. This strategic integration of technology aims to address gaps identified in previous studies and enhance the effectiveness of post-TAVI patient care. One significant concern after TAVI is the development of heart conduction abnormalities on the ECG and abnormal rhythms, such as heart block, potentially requiring permanent pacemaker insertion. Addressing these rhythm issues is crucial for reducing the overall length of stay.
Read full original descriptionShow less
The main question it aims to answer is: Does a remote patient monitoring protocol-driven strategy reduce post-TAVI hospital length of stay and adverse events? Participants post-TAVI procedure and eligible for same-day discharge, as determined by their primary cardiologist, will be randomized upon informed consent into the active arm (remote monitoring) or control group (standard of care).
Participants in the active arm will: receive four remote monitoring devices. Receive support from a validated clinical decision-making algorithm for further management.
Participants in the control group will: adhere to the best standard of care as per current practice.
Researchers will compare the active arm to the control group to see if the remote patient monitoring protocol-driven strategy reduces post-TAVI hospital length of stay and adverse events.
The 2 groups in the trial
- Control GroupOther group
The control group adheres to the best standard of care as per current practice.
Treatment: Standard Medical Therapy
- Remote Monitoring GroupExisting treatment, for comparison
Those in the remote monitoring group will be given four devices, which will help the research team make decisions about their health condition based on the data collected. The active arm group will wear the continuous ECG device for 72 hours from discharge and will be instructed to acquire a daily 12-lead ECG and record vital signs until day 7 of hospital discharge. Additionally, participants will utilise 12-lead ECG and vital signs will be measured only when experiencing symptoms.
Treatment: Remote Patient Monitoring Strategy
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Contact the study team: see the registry record → Contacts and Locations
Print a page for my doctorData and sources
- Registry record
- Listed on ClinicalTrials.gov.
- Official title
- Remote Acute Monitoring-based Same-day Discharge Strategy of Post Transcatheter Aortic Valve Implantation Patients Versus Standard Care at 30-Day Follow-up
- Plain-language title
- Remote monitoring after heart valve replacement for aortic valve stenosisGenerated from the registry record. The registry title is the official one.
- AI summary
- From the trial's eligibility criteria. Read by machine on 14 November 2026.
- Record updated
- 3 March 2026